RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Eurofins-Cerep Stock

Eurofins-Cerep ROE 2025

Eurofins-Cerep ROE

0.2

Ticker

ALECR.PA

ISIN

FR0013256518

WKN

A2DT0B

In 2025, Eurofins-Cerep's return on equity (ROE) was 0.2, a 0% increase from the 0 ROE in the previous year.

Eurofins-Cerep Aktienanalyse

What does Eurofins-Cerep do?

Eurofins-Cerep SA is a globally renowned biotechnology company that was founded in 1993. With its headquarters in Paris, France, the company operates over 47 locations worldwide and employs over 45,000 employees. The company specializes in the development and commercialization of innovative biological technologies for use in the pharmaceutical industry. Eurofins-Cerep focuses on the discovery of new drugs for the treatment of diseases such as cancer, Alzheimer's, Parkinson's, and diabetes. The business model of Eurofins-Cerep is based on three pillars: services, product sales, and research and development offerings. Under the "services" division, the company offers extensive pharmacological and biological testing and screening procedures for drug compounds to its customers. Eurofins-Cerep has a wide range of assays and tests that allow customers to assess and optimize the efficacy and safety of their drug compounds. The "product sales" division includes the manufacturing and distribution of over 1,000 different biological reagents, antibodies, and other products for biomedical research. The company specializes in producing reagents used in drug development, such as G-protein coupled receptors (GPCRs). The third pillar of Eurofins-Cerep's business model consists of research and development services for customers and partners. The company supports customers in identifying new drug compounds and developing drug candidates up to market approval. The company has various divisions, including the Cerep division, which specializes in the evaluation of potential drug candidates and associated toxicology. The Eurofins Pharma Discovery Services division offers advanced drug optimization and screening services by providing customized approaches to drug development. The Eurofins BioPharma Services division is a leading provider of complete solutions in the pharmaceutical development and GxP laboratories. The company is also active in other areas such as the environment and the food industry. Eurofins-Cerep has made several acquisitions in the past, including the acquisition of XDS Laboratories, a leading provider of clinical laboratory services, and EAG Laboratories, a highly specialized analysis and testing service unit. Overall, Eurofins-Cerep SA has achieved numerous milestones in the past 28 years and has become one of the world's leading providers of biological screening and analysis technologies. The company remains committed to offering its customers innovative biological technologies and maintaining its reputation as a reliable partner in the pharmaceutical industry. Eurofins-Cerep ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding Eurofins-Cerep's Return on Equity (ROE)

Eurofins-Cerep's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Eurofins-Cerep's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Eurofins-Cerep's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Eurofins-Cerep’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Eurofins-Cerep stock

What is the ROE (Return on Equity) of Eurofins-Cerep this year?

The ROE of Eurofins-Cerep this year is 0.2 undefined.

How has the Return on Equity (ROE) of Eurofins-Cerep developed compared to the previous year?

The ROE of Eurofins-Cerep has increased by 0% decreased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of Eurofins-Cerep?

A high ROE indicates that Eurofins-Cerep generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of Eurofins-Cerep?

A low ROE can indicate that Eurofins-Cerep is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of Eurofins-Cerep affect the company?

A change in ROE (Return on Equity) of Eurofins-Cerep can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of Eurofins-Cerep?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of Eurofins-Cerep?

Some factors that can influence Eurofins-Cerep's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does Eurofins-Cerep pay?

Over the past 12 months, Eurofins-Cerep paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Eurofins-Cerep is expected to pay a dividend of 0 EUR.

What is the dividend yield of Eurofins-Cerep?

The current dividend yield of Eurofins-Cerep is .

When does Eurofins-Cerep pay dividends?

Eurofins-Cerep pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Eurofins-Cerep?

Eurofins-Cerep paid dividends every year for the past 0 years.

What is the dividend of Eurofins-Cerep?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Eurofins-Cerep located?

Eurofins-Cerep is assigned to the 'Health' sector.

Wann musste ich die Aktien von Eurofins-Cerep kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Eurofins-Cerep from 1/21/2025 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 1/21/2025.

When did Eurofins-Cerep pay the last dividend?

The last dividend was paid out on 1/21/2025.

What was the dividend of Eurofins-Cerep in the year 2024?

In the year 2024, Eurofins-Cerep distributed 0 EUR as dividends.

In which currency does Eurofins-Cerep pay out the dividend?

The dividends of Eurofins-Cerep are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Eurofins-Cerep

Our stock analysis for Eurofins-Cerep Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Eurofins-Cerep Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.